Eisai Announces Strategic Investment Supported by the UK Government’s LSIMFStrategic investment in the Hatfield manufacturing site in the UK to help establish in-house capabilities for medicines requiring cold-chain management

Our news releases are intended to disclose corporate information and are not intended for the promotion or advertising of prescription pharmaceuticals or investigational products, nor are they intended to provide medical advice.
Please note that the information contained in news releases is current as of the date of publication.